{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:38:55Z","timestamp":1770817135144,"version":"3.50.1"},"reference-count":32,"publisher":"Becaris Publishing Limited","issue":"3","funder":[{"name":"Bayer Hispania","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            EMIR was a multicenter, prospective study, including 1433 AF patients taking rivaroxaban for \u22656\u00a0months. Data were analyzed according to the presence of vascular disease.\n            <jats:bold>Results:<\/jats:bold>\n            Coronary artery disease\u00a0was detected in 16.4%, peripheral artery disease\/aortic plaque in 6.7%, vascular disease in 28.3%. Patients with coronary artery disease had higher rates (per 100 patient-years) of major adverse cardiovascular events (2.98 vs 0.71; p\u00a0&lt;\u00a00.001) and cardiovascular death (1.79 vs 0.41; p\u00a0=\u00a00.004). Those with vascular disease had higher rates of thromboembolic events (1.47 vs 0.44; p\u00a0=\u00a00.007), major adverse cardiovascular events (2.03 vs 0.70; p\u00a0=\u00a00.004), and cardiovascular death (1.24 vs 0.39; p\u00a0=\u00a00.025). Patients with peripheral artery disease\/aortic plaque had similar rates.\n            <jats:bold>Conclusion:<\/jats:bold>\n            AF patients with vascular disease have a higher risk of non-embolic outcomes.\n          <\/jats:p>","DOI":"10.57264\/cer-2022-0049","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:52:44Z","timestamp":1676940764000},"source":"Crossref","is-referenced-by-count":2,"title":["Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban"],"prefix":"10.57264","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-7708","authenticated-orcid":false,"given":"Francisco","family":"Mar\u00edn","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBERCV, Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-4579","authenticated-orcid":false,"given":"Marcelo Sanmart\u00edn","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Ramon y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9103-4753","authenticated-orcid":false,"given":"Gonzalo","family":"Bar\u00f3n-Esquivias","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Virgen del Rocio, Universidad de Sevilla, Sevilla, Spain"},{"name":"Unidad Cardiovascular, Instituto de Biotecnolog\u00eda de Sevilla. Centro de Investigaci\u00f3n en Red Cardiovascular, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6135-7685","authenticated-orcid":false,"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Ram\u00f3n y Cajal, Alcal\u00e1 University, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0309-3770","authenticated-orcid":false,"given":"I\u00f1aki","family":"Lekuona","sequence":"additional","affiliation":[{"name":"Hospital Galdakao-Usansolo, Bizkaia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-4263","authenticated-orcid":false,"given":"Alejandro I","family":"P\u00e9rez-Cabeza","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Virgen de la Victoria University Hospital, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1329-0943","authenticated-orcid":false,"given":"Jaime","family":"Masjuan","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Departamento de Medicina, Universidad de Alcal\u00e1. Red INVICTUS, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Recalde","family":"del Vigo","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Basurto, Centro M\u00e9dico San Juan de Dios, Bizkaia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0888-6937","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"V\u00e1zquez Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Complejo Hospitalario Universitario A Coru\u00f1a, INIBIC, CIBERCV, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-4236","authenticated-orcid":false,"given":"Roman","family":"Freixa-Pamias","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Mois\u00e9s Broggi, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-6602","authenticated-orcid":false,"given":"Vanessa Rold\u00e1n","family":"Schilling","sequence":"additional","affiliation":[{"name":"Department of Haematology &amp; Clinical Oncology, Hospital Universitario Morales Meseguer. University of Murcia, Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-7923","authenticated-orcid":false,"given":"Fernando","family":"Arribas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario 12 de Octubre, Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain"},{"name":"Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), CIBERCV, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-6045","authenticated-orcid":false,"given":"Carles Rafols","family":"Priu","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Bayer Hispania, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-7263","authenticated-orcid":false,"given":"Manuel Anguita","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Reina Sof\u00eda C\u00f3rdoba, IMIBIC, University of Cordoba, C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge","volume":"16","author":"Lippi G","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int. J. Stroke 16(2), 217\u2013221 (2021).","journal-title":"Int. J. Stroke"},{"issue":"4","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41569-020-00459-3","article-title":"Stroke prevention strategies in high-risk patients with atrial fibrillation","volume":"18","author":"Kotalczyk A","year":"2021","unstructured":"Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat. Rev. Cardiol. 18(4), 276\u2013290 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijcard.2017.06.033","article-title":"The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: insights from the United Kingdom ACALM registry","volume":"252","author":"Ziff OJ","year":"2018","unstructured":"Ziff OJ, Carter PR, McGowan J The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: insights from the United Kingdom ACALM registry. Int. J. Cardiol. 252, 117\u2013121 (2018).","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/jcm10020198","article-title":"The multifaceted interplay between atrial fibrillation and myocardial infarction: a review","volume":"10","author":"Belkouche A","year":"2021","unstructured":"Belkouche A, Yao H, Putot A The multifaceted interplay between atrial fibrillation and myocardial infarction: a review. J. Clin. Med. 10(2), 198 (2021).","journal-title":"J. Clin. Med."},{"issue":"5","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"e003347","DOI":"10.1161\/JAHA.116.003347","article-title":"Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms","volume":"5","author":"Violi F","year":"2016","unstructured":"Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J. Am. Heart Assoc. 5(5), e003347 (2016).","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/clc.23344","article-title":"Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation","volume":"43","author":"Miao B","year":"2020","unstructured":"Miao B, Hernandez AV, Roman YM, Alberts MJ, Coleman CI, Baker WL. Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation. Clin. Cardiol. 43(5), 524\u2013531 (2020).","journal-title":"Clin. Cardiol."},{"issue":"5","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 42(5), 373\u2013498 (2021).","journal-title":"Eur. Heart J."},{"issue":"1","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14656566.2016.1267140","article-title":"Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation","volume":"18","author":"Mar\u00edn F","year":"2017","unstructured":"Mar\u00edn F, Anguita-S\u00e1nchez M, Sanmart\u00edn M. Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. Expert Opin. Pharmacother. 18(1), 67\u201377 (2017).","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"e_1_3_3_11_2","first-page":"222","article-title":"From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation","volume":"43","author":"Barrios V","year":"2017","unstructured":"Barrios V, Escobar C. From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation. Semergen 43(3), 222\u2013229 (2017).","journal-title":"Semergen"},{"issue":"14","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/eurheartj\/ehv532","article-title":"Assessing generalizability of trial results in general practice","volume":"37","author":"Pokorney SD","year":"2016","unstructured":"Pokorney SD, O'Brien EC, Granger CB. Assessing generalizability of trial results in general practice. Eur. Heart J. 37(14), 1154\u20131157 (2016).","journal-title":"Eur. Heart J."},{"issue":"14","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm AJ","year":"2016","unstructured":"Camm AJ, Amarenco P, Haas S XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur. Heart J. 37(14), 1145\u20131153 (2016).","journal-title":"Eur. Heart J."},{"issue":"7","key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/cer-2020-0286","article-title":"Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)","volume":"10","author":"Sanmartin-Fern\u00e1ndez M","year":"2021","unstructured":"Sanmartin-Fern\u00e1ndez M, Mar\u00edn F, Rafols C the EMIR Study Investigators. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J. Comp. Eff. Res. 10(7), 583\u2013593 (2021).","journal-title":"J. Comp. Eff. Res."},{"issue":"9","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"e13788","DOI":"10.1111\/eci.13788","article-title":"Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study","volume":"52","author":"L\u00f3pez-G\u00e1lvez R","year":"2022","unstructured":"L\u00f3pez-G\u00e1lvez R, Rivera-Caravaca JM, Anguita S\u00e1nchez M Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. Eur. J. Clin. Invest. 52(9), e13788 (2022).","journal-title":"Eur. J. Clin. Invest."},{"key":"e_1_3_3_16_2","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation, management of chronic kidney disease","volume":"3","author":"Kidney Disease, Improving Global Outcomes (KDIGO), CKD Work Group","year":"2013","unstructured":"Kidney Disease, Improving Global Outcomes (KDIGO), CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation, management of chronic kidney disease. Kidney Int. Suppl. 3, 1\u2013150 (2013).","journal-title":"Kidney Int. Suppl."},{"issue":"4","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of ant hemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman S","year":"2005","unstructured":"Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of ant hemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3(4), 692\u2013694 (2005).","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883\u2013891 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/eurheartj\/eht428","article-title":"Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial","volume":"35","author":"Mahaffey KW","year":"2014","unstructured":"Mahaffey KW, Stevens SR, White HD Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur. Heart J. 35(4), 233\u2013241 (2014).","journal-title":"Eur. Heart J."},{"issue":"4","key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/eurheartj\/eht492","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF","volume":"35","author":"Jones WS","year":"2014","unstructured":"Jones WS, Hellkamp AS, Halperin J Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur. Heart J. 35(4), 242\u2013249 (2014).","journal-title":"Eur. Heart J."},{"issue":"4","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey GJ","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 11(4), 315\u2013322 (2012).","journal-title":"Lancet Neurol."},{"issue":"8","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MCA.0000000000000031","article-title":"Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials","volume":"24","author":"Chatterjee S","year":"2013","unstructured":"Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron. Artery Dis. 24(8), 628\u2013635 (2013).","journal-title":"Coron. Artery Dis."},{"issue":"3","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ehjcvp\/pvz047","article-title":"Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease","volume":"6","author":"Coleman CI","year":"2020","unstructured":"Coleman CI, Baker WL, Meinecke AK Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. Eur. Heart J. Cardiovasc. Pharmacother. 6(3), 159\u2013166 (2020).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","article-title":"Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial","volume":"179","author":"Shah R","year":"2016","unstructured":"Shah R, Hellkamp A, Lokhnygina Y Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial. Am. Heart J. 179, 77\u201386 (2016).","journal-title":"Am. Heart J."},{"issue":"12","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda S","year":"2019","unstructured":"Yasuda S, Kaikita K, Akao M Antithrombotic therapy for atrial fibrillation with stable coronary disease. N. Engl. J. Med. 381(12), 1103\u20131113 (2019).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2017.06.110","article-title":"Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: results from ROCKET AF","volume":"257","author":"Barnett AS","year":"2018","unstructured":"Barnett AS, Cyr DD, Goodman SG Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: results from ROCKET AF. Int. J. Cardiol. 257, 78\u201383 (2018).","journal-title":"Int. J. Cardiol."},{"issue":"13","key":"e_1_3_3_27_2","first-page":"1290","article-title":"Rivaroxaban vs apixaban and ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"327","author":"Gu HQ","year":"2022","unstructured":"Gu HQ. Rivaroxaban vs apixaban and ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA 327(13), 1290 (2022).","journal-title":"JAMA"},{"issue":"2","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"368504211012160","DOI":"10.1177\/00368504211012160","article-title":"Rivaroxaban for cancer-associated venous thromboembolism","volume":"104","author":"Liang B","year":"2021","unstructured":"Liang B, Liang Y, Zhao LZ, Zhao YX, Gu N. Rivaroxaban for cancer-associated venous thromboembolism. Sci. Prog. 104(2), 368504211012160 (2021).","journal-title":"Sci. Prog."},{"issue":"10","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1253\/circrep.CR-20-0082","article-title":"Oral anticoagulant use in elderly japanese patients with non-valvular atrial fibrillation \u2013 subanalysis of the ANAFIE Registry","volume":"2","author":"Akao M","year":"2020","unstructured":"Akao M, Shimizu W, Atarashi H Oral anticoagulant use in elderly japanese patients with non-valvular atrial fibrillation \u2013 subanalysis of the ANAFIE Registry. Circ. Rep. 2(10), 552\u2013559 (2020).","journal-title":"Circ. Rep."},{"issue":"25","key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson CM","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 375(25), 2423\u20132434 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"e010476","DOI":"10.1161\/CIRCINTERVENTIONS.120.010476","article-title":"Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE trial","volume":"14","author":"Kaikita K","year":"2021","unstructured":"Kaikita K, Yasuda S, Akao M Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE trial. Circ. Cardiovasc. Interv. 14(11), e010476 (2021).","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"10","key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/pds.5228","article-title":"Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice","volume":"30","author":"Morimoto T","year":"2021","unstructured":"Morimoto T, Uchida K, Sakakibara F, Kinjo N, Ueda S. Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice. Pharmacoepidemiol. Drug Saf. 30(10), 1321\u20131331 (2021).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"20","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","article-title":"Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score","volume":"140","author":"Kaplan RM","year":"2019","unstructured":"Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score. Circulation 140(20), 1639\u20131646 (2019).","journal-title":"Circulation"},{"issue":"1","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ccep.2020.11.001","article-title":"Renal disease and atrial fibrillation","volume":"13","author":"Stefil M","year":"2021","unstructured":"Stefil M, Nabrdalik K, Lip GYH. Renal disease and atrial fibrillation. Card. Electrophysiol. Clin. 13(1), 95\u2013112 (2021).","journal-title":"Card. Electrophysiol. Clin."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2022-0049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:15:45Z","timestamp":1679231745000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.57264\/cer-2022-0049"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0049","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"article-number":"e220049"}}